×
It looks like you're using an obsolete version of internet explorer. Internet explorer is no longer supported by Microsoft since the end of 2015. We invite you to use a newer browser such as Firefox, Google Chrome or Microsoft Edge.
My Player placeholder

Become an Incathlab member and receive full access to its content!

You must be an Incathlab member to access videos without any restrictions. Register for free in one minute and access all services provided by Incathlab.You will also be able to log into Incathlab from your Facebook or twitter account by clicking on login on the top-right corner of Incathlab website.

Registration Login


Worldwide schedules comment Share
22559 views

Through an interactive discussion around video cases performed by expert operators, discover techniques and devices to improve the use of Drug Eluting Technologies, and how to choose DCB or DES for your patient's treatment.

Program

12:30 Introduction - Pr Torsello
12:30 Case in box n°1: Drug eluting stent for challenging long SFA lesion
Panel discussion
12:50 MAJESTIC trial: 3-year results 
Dr Bisdas
13:00 Case in box n°2: Subacute SFA occlusion 
Panel discussion
13:20 Post-market all-comers registry with the Eluvia stent: interim results
Dr Bisdas
13:30 Case in box n°3: Calcified lesion in the distal femoro-popliteal artery
Panel Discussion
13:50 Ranger DCB and all-comers registry: current data
Dr Stavroulakis
14:00 Take home messages - Pr Torsello


Educational objectives

  • Discuss current trends and approaches to the treatment of SFA lesions with the use of DES and DCB in long lesions, in terms of patient’s outcomes.
  • Learn and observe a step-by-step complex procedure with technical and strategical tips & tricks.
  • How to choose your strategy depending on clinical, anatomical and cost efficiency criteria.
  • Demonstrate advanced techniques and new drug eluting technologies in the treatment of peripheral artery disease.
  • Provide platform for discussion and mutual learning with your experts.

Audience

  • Endovascular specialists (Vascular Surgeons, Interventional Radiologists, Interventional Angiologists and Interventional Cardiologists).
  • Referring physicians of patients with peripheral artery disease.
Shooting date : 2017-10-06
Last update : 2018-01-14

Eluvia™ / Boston Scientific

Drug-Eluting Vascular Stent System

Ranger™ / Boston Scientific

Paclitaxel-Coated PTA Balloon Catheter

Promus PREMIER™ / Boston Scientific

Everolimus-Eluting Platinum Chromium Coronary Stent System

Mustang™ / Boston Scientific

0.035” Balloon Dilatation Catheter
4 comments
Join the Discussion
  • Arne S. Thank you, everybody, for joining our webinar. I hope you enjoyed it. All three cases were challenging femoropopliteal lesions and we would be more than happy to answer possible questions that you may have.

      Please, select your files, click upload button, write your comment and click the send button. (allowed formats : images jpeg, gif, png, and PDF)
      Your browser doesn't have Flash, Silverlight or HTML5 support.


    • Theodosios B. It was a really educational session and thank you for the very good questions regarding our approach for complex femoropopliteal lesions

        Please, select your files, click upload button, write your comment and click the send button. (allowed formats : images jpeg, gif, png, and PDF)
        Your browser doesn't have Flash, Silverlight or HTML5 support.


      • mohamad ali A. it was a nice meeting and a great job
        thank you dr. Theodosios and your colleagues

          Please, select your files, click upload button, write your comment and click the send button. (allowed formats : images jpeg, gif, png, and PDF)
          Your browser doesn't have Flash, Silverlight or HTML5 support.


          • Please, select your files, click upload button, write your comment and click the send button. (allowed formats : images jpeg, gif, png, and PDF)
            Your browser doesn't have Flash, Silverlight or HTML5 support.


          Suggestions

          Wednesday, October 23rd 2024 from 12pm to 12:30pm (GMT+2)
          Honolulu : Wednesday, October 23rd 2024 from 01am to 01:30am (GMT+2)
          San Francisco : Wednesday, October 23rd 2024 from 04am to 04:30am (GMT+2)
          New York : Wednesday, October 23rd 2024 from 07am to 07:30am (GMT+2)
          Buenos Aires : Wednesday, October 23rd 2024 from 08am to 08:30am (GMT+2)
          Reykjavik : Wednesday, October 23rd 2024 from 11am to 11:30am (GMT+2)
          London / Dublin : Wednesday, October 23rd 2024 from 12pm to 12:30pm (GMT+2)
          Paris / Berlin : Wednesday, October 23rd 2024 from 01pm to 01:30pm (GMT+2)
          Istanbul : Wednesday, October 23rd 2024 from 02pm to 02:30pm (GMT+2)
          Moscou / Dubaï : Wednesday, October 23rd 2024 from 03pm to 03:30pm (GMT+2)
          Bangkok : Wednesday, October 23rd 2024 from 06pm to 06:30pm (GMT+2)
          Shanghai : Wednesday, October 23rd 2024 from 07pm to 07:30pm (GMT+2)
          Tokyo : Wednesday, October 23rd 2024 from 08pm to 08:30pm (GMT+2)
          Sydney : Wednesday, October 23rd 2024 from 10pm to 10:30pm (GMT+2)
          Wellington : Thursday, October 24th 2024 from 12am to 12:30am (GMT+2)

          The Complex Made Simple: A Novel All-in-One Solution for Infrainguinal CTO

          Share
          0
          Days
          0
          Hours
          0
          Minutes
          0
          Seconds
          Friday, February 7th 2025 from 01pm to 03pm (GMT+1)
          Honolulu : Friday, February 7th 2025 from 02am to 04am (GMT+1)
          San Francisco : Friday, February 7th 2025 from 04am to 06am (GMT+1)
          New York : Friday, February 7th 2025 from 07am to 09am (GMT+1)
          Buenos Aires : Friday, February 7th 2025 from 09am to 11am (GMT+1)
          London / Dublin : Friday, February 7th 2025 from 12pm to 02pm (GMT+1)
          Paris / Berlin : Friday, February 7th 2025 from 01pm to 03pm (GMT+1)
          Istanbul : Friday, February 7th 2025 from 02pm to 04pm (GMT+1)
          Moscou / Dubaï : Friday, February 7th 2025 from 04pm to 06pm (GMT+1)
          Bangkok : Friday, February 7th 2025 from 07pm to 09pm (GMT+1)
          Shanghai : Friday, February 7th 2025 from 08pm to 10pm (GMT+1)
          Tokyo : Friday, February 7th 2025 from 09pm to 11pm (GMT+1)
          Sydney : Friday, February 7th 2025 from 10pm to 12am (GMT+1)
          Wellington : Saturday, February 8th 2025 from 12am to 02am (GMT+1)

          The Drug Eluting Technology Show

          Friday, February 23rd 2024 from 11am to 12:30pm (GMT+1)
          Honolulu : Friday, February 23rd 2024 from 12am to 01:30am (GMT+1)
          San Francisco : Friday, February 23rd 2024 from 02am to 03:30am (GMT+1)
          New York : Friday, February 23rd 2024 from 05am to 06:30am (GMT+1)
          Buenos Aires : Friday, February 23rd 2024 from 07am to 08:30am (GMT+1)
          London / Dublin : Friday, February 23rd 2024 from 10am to 11:30am (GMT+1)
          Paris / Berlin : Friday, February 23rd 2024 from 11am to 12:30pm (GMT+1)
          Istanbul : Friday, February 23rd 2024 from 12pm to 01:30pm (GMT+1)
          Moscou / Dubaï : Friday, February 23rd 2024 from 02pm to 03:30pm (GMT+1)
          Bangkok : Friday, February 23rd 2024 from 05pm to 06:30pm (GMT+1)
          Shanghai : Friday, February 23rd 2024 from 06pm to 07:30pm (GMT+1)
          Tokyo : Friday, February 23rd 2024 from 07pm to 08:30pm (GMT+1)
          Sydney : Friday, February 23rd 2024 from 08pm to 09:30pm (GMT+1)
          Wellington : Friday, February 23rd 2024 from 10pm to 11:30pm (GMT+1)

          Realizing the PAD Workflow of the Future

          A more efficient and Versatile Approach to Complex Lesions

          Share
          Thursday, October 28th 2021 from 06pm to 07pm (GMT+2)
          Honolulu : Thursday, October 28th 2021 from 07am to 08am (GMT+2)
          San Francisco : Thursday, October 28th 2021 from 10am to 11am (GMT+2)
          New York : Thursday, October 28th 2021 from 01pm to 02pm (GMT+2)
          Buenos Aires : Thursday, October 28th 2021 from 02pm to 03pm (GMT+2)
          Reykjavik : Thursday, October 28th 2021 from 05pm to 06pm (GMT+2)
          London / Dublin : Thursday, October 28th 2021 from 06pm to 07pm (GMT+2)
          Paris / Berlin : Thursday, October 28th 2021 from 07pm to 08pm (GMT+2)
          Istanbul : Thursday, October 28th 2021 from 08pm to 09pm (GMT+2)
          Moscou / Dubaï : Thursday, October 28th 2021 from 09pm to 10pm (GMT+2)
          Bangkok : Friday, October 29th 2021 from 12am to 01am (GMT+2)
          Shanghai : Friday, October 29th 2021 from 01am to 02am (GMT+2)
          Tokyo : Friday, October 29th 2021 from 02am to 03am (GMT+2)
          Sydney : Friday, October 29th 2021 from 04am to 05am (GMT+2)
          Wellington : Friday, October 29th 2021 from 06am to 07am (GMT+2)

          Strategies for Successful Management of Complex Long Lesions

          Share
          Thursday, November 4th 2021 from 05pm to 06:15pm (GMT+1)
          Honolulu : Thursday, November 4th 2021 from 06am to 07:15am (GMT+1)
          San Francisco : Thursday, November 4th 2021 from 08am to 09:15am (GMT+1)
          New York : Thursday, November 4th 2021 from 11am to 12:15pm (GMT+1)
          Buenos Aires : Thursday, November 4th 2021 from 01pm to 02:15pm (GMT+1)
          London / Dublin : Thursday, November 4th 2021 from 04pm to 05:15pm (GMT+1)
          Paris / Berlin : Thursday, November 4th 2021 from 05pm to 06:15pm (GMT+1)
          Istanbul : Thursday, November 4th 2021 from 06pm to 07:15pm (GMT+1)
          Moscou / Dubaï : Thursday, November 4th 2021 from 08pm to 09:15pm (GMT+1)
          Bangkok : Thursday, November 4th 2021 from 11pm to 12:15am (GMT+1)
          Shanghai : Friday, November 5th 2021 from 12am to 01:15am (GMT+1)
          Tokyo : Friday, November 5th 2021 from 01am to 02:15am (GMT+1)
          Sydney : Friday, November 5th 2021 from 02am to 03:15am (GMT+1)
          Wellington : Friday, November 5th 2021 from 04am to 05:15am (GMT+1)

          Challenges of fempop interventions – Crossing of complex lesions and preventing restenosis

          Swirling Flow: a replacement for anti-proliferative coating?

          Share
          Scroll Up